Members of a new class of antivirals are being tested in U.S. clinical trials, and one has gained approval in Japan, but how ...
A new study published in Otolaryngology–Head and Neck Surgery reveals that glucagon-like peptide-1 receptor agonists ...
With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.
New research reveals these medications impact everything from heart health to restaurant menus.
Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...
A new study headed by teams at the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), and Open Targets has indicated how mutations that cause cancer drug resistance fall ...
Psychiatric illness does not exist in isolation, and concomitant disorders such as dyslipidemia and glucose irregularities must be taken into account when viewing the whole clinical picture. Therefore ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results